Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
– ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027 – ECLIPSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results